Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Q Chu

Showing results (151-160 of 193) with videos related to

Pageof 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaL Zhang, F Zhu, L Xie, et al.
Oncogene|November 17, 2015
EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loopC-F Yang, G-D Yang, T-J Huang, et al.
Clinical Lung Cancer|October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master ProtocolJ Spicer, N Blais, S Owen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2015
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancerG Giaccone, L A Bazhenova, J Nemunaitis, et al.
ESMO Open|February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)K He, P M Forde, R Govindan, et al.
Scientific Reports|March 5, 2025
Spontaneous evolution of density peaking factor in TEM turbulence-dominated H-mode plasma on the EAST TokamakJ S Geng, P Li, Y D Li, et al.
ESMO Open|February 12, 2022
Consensus for HER2 alterations testing in non-small-cell lung cancerS Ren, J Wang, J Ying, et al.
ESMO Open|April 23, 2022
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]S Ren, J Wang, J Ying, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2020
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinomaG Lin, C Li, P S Li, et al.
Pageof 20

Showing results (151-160 of 193) with videos related to

Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaL Zhang, F Zhu, L Xie, et al.
Oncogene|November 17, 2015
EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loopC-F Yang, G-D Yang, T-J Huang, et al.
Clinical Lung Cancer|October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master ProtocolJ Spicer, N Blais, S Owen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 19, 2015
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancerG Giaccone, L A Bazhenova, J Nemunaitis, et al.
ESMO Open|February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)K He, P M Forde, R Govindan, et al.
Scientific Reports|March 5, 2025
Spontaneous evolution of density peaking factor in TEM turbulence-dominated H-mode plasma on the EAST TokamakJ S Geng, P Li, Y D Li, et al.
ESMO Open|February 12, 2022
Consensus for HER2 alterations testing in non-small-cell lung cancerS Ren, J Wang, J Ying, et al.
ESMO Open|April 23, 2022
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]S Ren, J Wang, J Ying, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2020
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinomaG Lin, C Li, P S Li, et al.
Pageof 20